Background-Prognosis and survival are significant concerns for individuals with heart failure (HF). To better understand the pathophysiology of HF prognosis, the association between 2 366 858 single-nucleotide polymorphisms (SNPs) and all-cause mortality was evaluated among individuals with incident HF from 4 community-based prospective cohorts: the Atherosclerosis Risk in Communities Study, the Cardiovascular Health Study, the Framingham Heart Study, and the Rotterdam Study. Methods and Results-Participants were 2526 individuals of European ancestry and 466 individuals of African ancestry who experienced an incident HF event during follow-up in the respective cohorts. Within each study, the association between genetic variants and time to mortality among individuals with HF was assessed by Cox proportional hazards models that included adjustment for sex and age at the time of the HF event. Prospective fixed-effect meta-analyses were conducted for the 4 study populations of European ancestry (Nϭ1645 deaths) and for the 2 populations of African ancestry (Nϭ281 deaths). Genome-wide significance was set at Pϭ5.0ϫ10 Ϫ7 . Meta-analytic findings among individuals of European ancestry revealed 1 genome-wide significant locus on chromosome 3p22 in an intron of CKLF-like MARVEL transmembrane domain containing 7 (CMTM7, Pϭ3.2ϫ10 Ϫ7 ). Eight additional loci in individuals of European ancestry and 4 loci in individuals of African ancestry were identified by high-signal SNPs (PϽ1.0ϫ10 Ϫ5 ) but did not meet genome-wide significance. Conclusions-This study identified a novel locus associated with all-cause mortality among individuals of European ancestry with HF. This finding warrants additional investigation, including replication, in other studies of HF. (Circ Cardiovasc Genet. 2010;3:248-255.)
H eart failure (HF) is a relatively common chronic condition characterized by the inability of the heart to efficiently pump blood and represents a significant public health burden, affecting nearly 6 million Americans. Prognosis and survival are a significant concern; after HF is diagnosed, 1 in 5 die within 1 year, 1 often by sudden cardiac death, which occurs 6 to 9 times more often than in the general population. 1, 2 
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The public health burden of HF and its associated mortality are likely to intensify because of the aging population and an increase in the prevalence of HF risk factors, such as coronary artery disease, obesity, and diabetes. The Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium includes the Atherosclerosis Risk in Communities (ARIC) Study, the Cardiovascular Health Study (CHS), the Framingham Heart Study (FHS), the Rotterdam Study (RS), and the National Institute of Aging's Iceland Age, Gene/ Environment Susceptibility Study. 3 The CHARGE consortium provided an opportunity to evaluate genetic factors associated with the prognosis of HF, and the association between genome-wide variation and all-cause mortality was investigated among 2526 incident HF cases of European ancestry and 466 incident HF cases of African ancestry. 4 
Methods

Design and Study Population
The design for this study is a cohort of individuals with incident HF nested within 4 of the population-based studies (ARIC, CHS, FHS, and RS) of the CHARGE consortium. A detailed description of each cohort study design has been published elsewhere. [5] [6] [7] [8] [9] Selection of eligible incident HF cases (with available genome-wide scan data) and methodology for genotyping and genotype imputation are published. 4 HF cases were identified during 1987-2004 for ARIC, 1989 -2007 for CHS, 1988 CHS, -2006 for FHS, and 1990 -2006 for RS. Details regarding HF diagnostic criteria are shown in supplemental Table I. In brief, eligible participants for these analyses were individuals of European or African ancestry who experienced an incident HF event during follow-up and had genome-wide association data. Identification of incident HF events relied on multiple sources of clinical and administrative data. The approach was similar across the 4 studies and is described in more detail in previously published reports. 4, 10, 11 A total of 2526 incident HF events were identified from 20 926 participants of European ancestry from all 4 cohorts over a weighted average of 11.5 years of follow-up. 4 A total of 466 HF events were identified over an average of 13.7 years among 2895 individuals of African ancestry from ARIC and CHS. 4 Each study received institutional review board approval, and all participants provided written informed consent for the use of their DNA for research.
Genotyping and Imputation
For the individuals of European ancestry, each study independently imputed their genotype data to Ϸ2.4 million autosomal single-nucleotide polymorphisms (SNPs) identified in HapMap CEU samples. For this study, imputation genotypes were not determined in ARIC individuals of African ancestry, and genotypes available for analysis were restricted to successfully genotyped SNPs on the Affymetrix 6.0 chip. In CHS individuals of African ancestry, SNP data were imputed using information from HapMap YRI and CEU samples and were then restricted to the same set of SNPs evaluated in ARIC individuals of African ancestry. Imputation results were summarized as an "allele dosage" defined as the expected number of copies of the minor allele at that SNP (a fractional value between 0.0 and 2.0). A ratio of observed versus expected variance of the dosage for each SNP was calculated within each cohort as a measure of imputation quality.
Characteristics of Participants With HF
For these analyses, measures of clinical and demographic characteristics were obtained from the clinical visit preceding HF onset. At in-person visits, clinical measures were collected (annually in CHS from 1989 -1999, biennially in the original cohort, and approximately every 4 years in the offspring cohort of FHS, every 3 years in ARIC through 1998, and every 3 years in RS). Measures were taken using standardized methods as specified by each study and included in-person measures of height, weight, systolic and diastolic blood pressure, and total cholesterol. Each study also identified individuals with hypertension, diabetes, or myocardial infarction that occurred before HF diagnosis.
Mortality Ascertainment
Participants were prospectively followed up with in-person visits and telephone contact in most cohorts. Deaths were defined as all-cause mortality. In the ARIC study, deaths were ascertained through annual phone calls or through ongoing surveillance of health department death certificate files through December 31, 2004. In CHS, participant mortality was identified at 6-month surveillance contacts, National Death Index searches, and from obituaries through June 30, 2007. Additional information about cause of death was collected from death certificates, proxy interviews, and medical records. 11 In the RS, deaths were ascertained through general practitioner medical records and from municipal records through January 1, 2007. All FHS participants are under continuous surveillance based on periodic Heart Study visits and biannual health history updates. Information on death (and cause of death) is obtained from hospitalization records, medical records, death certificate, family members, and obituaries. All deaths are reviewed by an end points adjudication panel consisting of 3 FHS physicians. The mortality ascertainment rate for each cohort is Ͼ99%.
Statistical Analyses
The association between genomic variation and time to death among individuals with incident HF was evaluated separately in each cohort by Cox proportional hazards models. The follow-up time interval was defined as the time between the date of incident HF and the date of death, last contact if lost to follow-up, or the end of follow-up, whichever came first. Each model was evaluated separately in individuals with HF of European or African ancestry and included adjustment for sex and age at the time of the HF event. In addition, CHS adjusted for study site, and FHS adjusted for generation and ancestry using principal components. 12 ARIC and RS did not include additional adjustments in the analysis model. All SNPs were evaluated for association under an additive genetic model.
Across the 4 study populations of European ancestry and separately the 2 populations of African ancestry, fixed-effect meta-analyses combined ␤-coefficients and study-specific P values using genomic control lambdas to adjust for remaining population substructure. The meta-analysis produced an overall hazards ratio (HR), standard error, and a P value. Before meta-analysis, a filter was applied to SNPs with a ␤-coefficient Ͼ5.0 or ϽϪ5.0 to avoid numeric instabilities. Meta-analyses were performed using MetABEL software (http://mga.bionet-.nsc.ru/Ϸyurii/ABEL/) 13 and METAL (http://www.sph.umich.edu/csg/ abecasis/Metal/index.html) for confirmation. To avoid inaccuracies in the asymptotic assumptions of Cox models when the number of events carrying the variant allele was small (ie, Ͻ70 individuals with an end point and carrying the minor allele), SNPs were excluded from further consideration when the postmeta-analysis population size-weighted minor allele frequency (MAF) was Յ0.03 in individuals of European ancestry and Յ0.135 in individuals of African ancestry.
For each ancestry group, a quantile-quantile plot was generated from Cox proportional hazards models and shows the distribution of the observed and expected P values for all SNPs. Also, meta-analyzed P values were plotted according to location across the 22 autosomes. An a priori threshold of 5.0ϫ10 Ϫ7 was used to indicate genome-wide significance in the analysis of individuals of European and African ancestry. 14 High-signal SNPs had a P value Ͻ1.0ϫ10 Ϫ5 but did not meet genome-wide significance. If more than 1 significant or high-signal SNP clustered at a locus, the SNP with the smallest P value was reported as the locus marker. Regional plots showing detailed linkage disequilibrium and gene location information and forest plots were created for genome-wide significant markers. Additionally, top hits from the meta-analysis in the European and African ancestry populations were compared. The MAFs, HRs, and P values for these markers are reported for each ancestral population.
Results
Among the 2526 participants of European ancestry with incident HF, a total of 1645 deaths from all causes occurred at a weighted average of 3.6 years. A total of 281 deaths occurred among the 466 individuals with incident HF of African ancestry at a weighted average of 3.4 years. Baseline characteristics of cohort participants with incident HF are shown in Table 1 . The weighted average age at diagnosis of HF was 77.3 years (range from 44 to 101) among individuals of European ancestry and 70.0 years (range from 46 to 96) among individuals of African ancestry. Figure 1 shows the quantile-quantile plot of P values derived from the Ϸ2.4 million tests performed in participants of European ancestry plotted against the expected distribution. Except for some of the very lowest P values, the observed and expected distributions of P values were similar. The genomic inflation lambda values for the individual cohorts were 0.95 for CHS, 0.99 for RS, 1.00 for ARIC, and 1.09 for FHS. The meta-analysis genomic inflation lambda value for those of European ancestry was equal to 1.0, suggesting minimal population stratification or other technical artifacts. Figure 2 presents P values for the Ϸ2.4 million SNPs organized by chromosome and genomic position. As shown in Table 2 , 1 SNP (rs12638540, P valueϭ3.21ϫ10 Ϫ7 , HRϭ1.53, genome-wide confidence interval 1.01 to 2.31, MAF of 0.04) on chromosome 3p22 exceeded the prespecified genome-wide significance threshold. EA indicates European ancestry; and AA, African ancestry. *Self-reported history of treated hypertension and diabetes was determined in CHS and FHS. In RS, the definition of hypertension included use of antihypertensive medication and measured blood pressure (systolic blood pressure Ͼϭ160 mm Hg, diastolic blood pressure Ͼϭ100), and diabetes was defined by fasting glucose Ͼ126 or nonfasting glucose Ͼ198, or use of insulin or oral antidiabetics. Measurements of blood pressure and blood glucose were also used for the diagnosis of hypertension and diabetes in FHS, using standardized criteria. In the ARIC study, the definition of hypertension included use of antihypertensive medication and measured blood pressure (systolic blood pressure Յ140 mm Hg, diastolic blood pressure Յ90 mm Hg), and diabetes was defined by a fasting glucose level Յ126 mg/dL, a nonfasting glucose level Յ200 mg/dL, or a self-reported diagnosis of diabetes or use of diabetic medication.
Participants of European Ancestry
†Myocardial infarction that occurs before HF diagnosis. ‡Among individuals with heart failure. This SNP resides in an intron of CKLF-like MARVEL transmembrane domain containing 7 (CMTM7) and was genotyped in RS and FHS and imputed with high quality in ARIC (observed versus expected varianceϭ0.981) and CHS (observed versus expected varianceϭ0.921). Figure 3 presents detailed information about linkage disequilibrium structure and P values for other SNPs in this region, and a forest plot of the meta-analysis findings is shown in Figure 4 .
In addition to the 1 SNP exceeding genome-wide significance, 14 additional high-signal SNPs were identified with P values Ͻ1.0ϫ10 Ϫ5 that marked 8 chromosomal regions of interest. Table 2 provides details about those loci identified in individuals of European ancestry. Of these 8 loci, the ovarian tumor (OTU) domain containing 7A (OTUD7A), glycoprotein M6A (GPM6A), alpha parvin (PARVA), and interferonrelated developmental regulator 1 (IFRD1) genes were identified by a single intronic SNP. An intergenic SNP on chromosome 19 was 34.6 kb from the latrophilin 1 (LPHN1) gene. An intergenic SNP on chromosome 10 was 46.6 kb from the potassium large conductance calcium-activated channel, subfamily M, alpha member 1 (KCNMA1) gene, and an intergenic SNP on chromosome 5 was 77.6 kb from the Figure 5 shows the quantile-quantile plot of P values derived from the 560 383 tests performed in participants of African ancestry. Except for some of the very lowest P values, the observed and expected distributions of P values were similar. Figure 6 presents all P values organized by chromosome and genomic position. In individuals of African ancestry with incident HF, no SNP exceeded the prespecified genome-wide significance threshold for an association with mortality. Five high-signal SNPs were identified with P values Ͻ1.0ϫ10 Ϫ5 that marked 4 loci of interest ( Table 2 ). The smallest P value among individuals of African ancestry was for an intronic SNP in the a disintegrin and metalloproteinase with thrombospondin type 1 motif, 12 (ADAM) metallopeptidase with thrombospondin type 1 motif, 12 (ADAMTS12) gene. Two SNPs were within 27.7 kb from the potassium channel, subfamily K, member 13 (KCNK13) gene, and 1 SNP was in the promoter region of F-box protein 34 (FBXO34). An additional intergenic SNP was Ͼ100 kb from a known gene on chromosome 1. Cohort-specific results are provided in supplemental Table II .
Participants of African Ancestry
Cross-Ancestry Comparisons
None of the loci identified in the African ancestry analysis were associated with mortality in individuals with HF of European ancestry (all P values Ͼ0.05). The genome-wide significant and high-signal SNPs among individuals of European ancestry were not associated with mortality among African ancestry CHS participants (all P values Ͼ0.05). These SNPs were only imputed and evaluated for an association in CHS participants of African ancestry and were not imputed in individuals of African ancestry from the ARIC study. The MAF for rs12638540 is 0.07 in CHS individuals with HF of African ancestry.
Discussion
This study evaluated the association between genome-wide genetic variation and all-cause mortality among individuals with incident HF. The meta-analysis included 2526 individuals of European ancestry with HF and revealed an intronic SNP in CMTM7 on chromosome 3 that exceeded genomewide significance and was associated with a 53% increase in risk of death. Approximately 8% of the HF population carried this variant. Among African ancestry participants, no SNP had a P value that exceeded genome-wide significance. Additional high-signal SNPs identified in either the European or African ancestry populations were in or close to LPHN1, OTUD7A, GPM6A, PARVA, KCNMA1, IFRD1, SLC25A46, ADAMTS12, KCNK13, and FBXO34 (P value range between 1.10ϫ10 Ϫ6 and 9.64ϫ10 Ϫ6 ). Regions of the genome without known genes also identified in these analyses reside on chromosome 1q41 and 12q24. SNPs identified in a genomewide association study (GWAS) for incident HF 4 did not overlap with those identified here. The genome-wide significant association was for CMTM7, 1 of several chemokine-like factor genes clustered in the same region on chromosome 3p22. The protein encoded by CMTM7 is highly expressed in leukocytes and is also expressed in the heart, but its function is unknown. A recent study indicates that chemokine receptor gene expression is upregulated among patients with HF compared with controls. 15 The CMTM7 chemokine-like factor may act as a chemoattractant to guide migration of cells in the heart. Some chemokines play a role as a proinflammatory marker in the context of an immune response or may promote angiogenesis during HF.
Of the 12 loci that did not meet genome-wide significance, 4 merit further discussion. The observed association with OTUD7A in individuals of European ancestry and the association with FBXO34 in individuals of African ancestry suggest that these genes may play a role in HF progression and survival by contributing to inadequate degradation of ubiquitin-protein conjugates and resulting in autophagic myocyte death. A mouse model for desmin-related cardiomyopathy indicates that accumulation of polyubiquitinated proteins is correlated with hastened HF progression. 16 Other studies show that ubiquitinated proteins accumulate in the cytosol of human hearts with idiopathic or ischemic cardiomyopathies. 17, 18 The observed association with potassium channels encoded by KCNMA1 in individuals of European ancestry and KCNK13 in individuals of African ancestry provides evidence that control of vascular tone and regulation of the contraction of cardiac smooth muscle may be important components of HF progression and survival. Substantial previous work has documented that potassium channels are associated with cardiovascular and mortality end points. 19 -24 Although there was not a consistent finding for a particular SNP across the European and African ancestry populations, genes involved in deubiquitinating activity and genes encoding potassium channels were identified in each ethnic group. It is important to note that for many loci, there was a clear difference in the MAF between ethnic groups. This difference in MAF coupled with variable patterns of linkage disequilibrium between the populations obfuscates the interpretability of cross-ancestral comparisons. In addition, it is known that certain HF treatments affect length of survival with HF, and access to care and treatment practices are known to vary by region and ethnicity. 25, 26 
Study Strengths and Limitations
Although this is the largest study to date of individuals with incident HF evaluated for an association between genomewide genetic variation and all-cause mortality, there are study limitations also. SNP imputation in individuals of European ancestry resulted in the ability to meta-analyze results across Ϸ2.4 million SNPs. Given 2.4 million tests, 1 significant SNP is what would have been expected by chance for the a priori level of genome-wide significance and only 1 SNP exceeded this threshold in individuals of European ancestry. This finding may represent a false-positive result and requires replication in other studies. Similarly, the number of high-signal loci identified in either ancestry groups was far fewer than would be expected by chance given a threshold of Pϭ1.0ϫ10 Ϫ5 .
For some variants, imputation quality varied, and there was reduced statistical power to detect an association for poorly imputed SNPs. Cross-ancestry comparisons were limited to data from CHS individuals of African ancestry, and the overall statistical power to detect an association was limited in African ancestry participants given a total sample of 466 individuals.
Because of limited data availability across the cohorts, this study did not account for ejection fraction, treatment for HF, socioeconomic status, access to medical care, or hospitalizations subsequent to HF diagnosis. Heterogeneity among the individuals investigated for this study may have resulted from variation in HF diagnostic criteria across the 4 studies. However, a study comparing diagnostic criteria between CHS and FHS showed that all-cause mortality rates were similar across these diagnostic classifications. 27 A study evaluating HF diagnosis by central adjudication compared with hospital discharge diagnoses showed that mortality rates are similar. 28 A limitation of this study is that, given differences in diagnostic criteria, the HF cases may not represent the same disease. Because the 4 study populations likely comprise both systolic and diastolic HF, it is important to note that the cause of death may be markedly different between these 2 disease states. This study addressed all-cause mortality, and there was lack of information across cohorts to adequately conduct analyses of cause-specific mortality.
Finally, the observed signals are described in the context of the nearest gene; however, it is possible that true causal variants may be in neighboring genes or intergenic regions. Additional signals may have been missed because of coverage in particular genomic regions or the lack of statistical power to detect modest effects.
Conclusions
This study investigated 2526 incident HF cases of European ancestry from ARIC, CHS, FHS, and RS and 466 incident HF cases of African ancestry from ARIC and CHS for an association between genome-wide variation and all-cause mortality. One SNP in CMTM7 was significantly associated with all-cause mortality in individuals of European ancestry with HF, suggesting a role of chemokines with survival.
However, no SNP was found to be significantly associated with mortality in individuals with HF of African ancestry. Future studies of this type, especially those that address some of the limitations of this study, may identify genes that lead to an improved understanding of HF pathophysiology and treatment of the disease. These findings warrant additional investigation, including replication, in other studies of HF. 
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